Phase I clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Ishikawa, Takeshi ^a,b   Kokura, Satoshi ^a,b   Enoki, Tatsuji ^c   Sakamoto, Naoyuki ^a   Okayama, Tetsuya ^a,b   Ideno, Mitsuko ^c   Mineno, Junichi ^c   Uno, Kazuko ^d   Yoshida, Naohisa ^a   Kamada, Kazuhiro ^a   Katada, Kazuhiro ^a   Uchiyama, Kazuhiko ^a   Handa, Osamu ^a   Takagi, Tomohisa ^a   Konishi, Hideyuki ^a   Yagi, Nobuaki ^a   Naito, Yuji ^a   Itoh, Yoshito ^a   Yoshikawa, Toshikazu ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c TAKARA BIO INC   (Japan)

^d Louis Pasteur Center for Medical Research   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD27 ANTIGEN; CD28 ANTIGEN; CD45RA ANTIGEN; CYTOKINE; FIBRONECTIN; FIBRONECTIN CH296; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; RETRONECTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CD45 ANTIGEN; RECOMBINANT PROTEIN;

ADOPTIVE TRANSFER; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL THERAPY; CELL TRANSFER; CLINICAL ARTICLE; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FIBRONECTIN CH296 STIMULATED T CELL THERAPY; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; ADOPTIVE IMMUNOTHERAPY; CLINICAL TRIAL; FOLLOW UP; IMMUNOLOGY; METABOLISM; NEOPLASMS; T LYMPHOCYTE; TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; AGED; ANOREXIA; ANTIGENS, CD27; ANTIGENS, CD28; ANTIGENS, CD45; CYTOKINES; FATIGUE; FEMALE; FIBRONECTINS; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MIDDLE AGED; NEOPLASMS; RECOMBINANT PROTEINS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84900334859     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083786     Document Type: Article

References (31)

1. Childs RW, Barrett J (2004) Nonmyeloablative allogeneic immunotherapy for solid tumors. Annu Rev Med 55: 459-475. (Pubitemid 38316737)
2. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, et al. (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115: 1616-1626. (Pubitemid 40814670)
3. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, et al. (2004) Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 173: 7125-7130. (Pubitemid 39628146)
4. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, et al. (2005) Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 175: 7046-7052. (Pubitemid 41598952)
5. Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, et al. (2005) Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 28: 258-267. (Pubitemid 40593992)
6. Weng NP, Levine BL, June CH, Hodes RJ (1995) Human naive and memory T lymphocytes differ in telomeric length and replicative potential. Proc Natl Acad Sci U S A 92: 11091-11094.
7. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, et al. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854. (Pubitemid 35231542)
8. Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK (1998) Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8: 615-623. (Pubitemid 28264752)
9. Ruoslahti E (1988) Fibronectin and its receptors. Annu Rev Biochem 57: 375-413.
10. Hynes RO (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25.
11. Nojima Y, Rothstein DM, Sugita K, Schlossman SF, Morimoto C (1992) Ligation of VLA-4 on T cells stimulates tyrosine phosphorylation of a 105-kD protein. J Exp Med 175: 1045-1053.
12. Sato T, Tachibana K, Nojima Y, D'Avirro N, Morimoto C (1995) Role of the VLA-4 molecule in T cell costimulation. Identification of the tyrosine phosphorylation pattern induced by the ligation of VLA-4. J Immunol 155: 2938-2947.
13. Yu SS, Nukaya I, Enoki T, Chatani E, Kato A, et al. (2008) In vivo persistence of genetically modified T cells generated ex vivo using the fibronectin CH296 stimulation method. Cancer Gene Ther 15: 508-516.
14. Gattinoni L, Powell DJ, Jr., Rosenberg SA, Restifo NP (2006) Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6: 383-393.
15. Uno K, Nakano K, Maruo N, Onodera H, Mata H, et al. (1996) Determination of interferon-alpha-producing capacity in whole blood cultures from patients with various diseases and from healthy persons. J Interferon Cytokine Res 16: 911-918. (Pubitemid 26400683)
16. Takeshi Ishikawa SK, Naoyuki Sakamoto, Tsuguhiro Matsumoto, Jun Funaki, Satoko Adachi, et al. (2011) Adoptive cellular therapy enhances the helper T cell response and reduces the number of regulatory T cells. Experimental and Therapeutic Medicine 2: 737-743.
17. Ishikawa T, Kokura S, Sakamoto N, Okajima M, Matsuyama T, et al. (2012) Relationship between circulating cytokine levels and physical or psychological functioning in patients with advanced cancer. Clin Biochem 45: 207-211.
18. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, et al. (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756-2761. (Pubitemid 34921025)
19. Ishikawa T, Kokura S, Sakamoto N, Matsumoto T, Funaki J, et al. (2011) Adoptive cellular therapy enhances the helper T cell response and reduces the number of regulatory T cells. Exp Ther Med 2: 737-743.
20. Ishikawa T, Kokura S, Sakamoto N, Okayama T, Endo M, et al. (2013) Whole blood interferon-gamma levels predict the therapeutic effects of adoptive T-cell therapy in patients with advanced pancreatic cancer. Int J Cancer.
21. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, et al. (2002) Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8: 379-385. (Pubitemid 34407033)
22. Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, et al. (1997) Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 186: 1407-1418. (Pubitemid 27479800)
23. Acuto O, Michel F (2003) CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 3: 939-951. (Pubitemid 37521536)
24. Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, et al. (2000) CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 1: 433-440.
25. Powell DJ, Jr., Dudley ME, Robbins PF, Rosenberg SA (2005) Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105: 241-250. (Pubitemid 40053089)
26. Romagnani S (1991) Human TH1 and TH2 subsets: doubt no more. Immunol Today 12: 256-257.
27. Metcalf D, Begley CG, Johnson GR, Nicola NA, Vadas MA, et al. (1986) Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood 67: 37-45. (Pubitemid 16167008)
28. Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4: 11-22.
29. Matsumoto T, Kokura S, Ishikawa T, Funaki J, Adachi S, et al. (2011) Decrease of the regulatory T-cell population by adoptive T-cell transfer in a mouse colorectal cancer transplant model. Oncol Res 19: 543-554.
30. Stroncek DF, Berger C, Cheever MA, Childs RW, Dudley ME, et al. (2012) New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med 10: 48.
31. Turtle CJ, Hudecek M, Jensen MC, Riddell SR (2012) Engineered T cells for anti-cancer therapy. Curr Opin Immunol 24: 633-639.